Relationship between bone mineral density and biochemical markers of bone turnover in hemodialysis patients

Advances in Therapy

Volumn 24, Issue 5, 2007, Pages 987-995

  Sit, Dede ^a   Kadiroglu, Ali Kemal ^a   Kayabasi, Hasan ^b   Atay, A Engin ^c   Yilmaz, Zulfukar ^a   Yilmaz, M Emin ^a  

^a DICLE UNIVERSITY   (Turkey)

^b Patnos State (Government) Hospital   (Turkey)

^c Government Hospital   (Turkey)

Author keywords

Biochemical markers; Bone mineral density; Hemodialysis patients

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BICARBONATE; BIOCHEMICAL MARKER; CALCIUM; CALCIUM ION; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; ARTICLE; ARTIFICIAL KIDNEY; BLOOD PH; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HEMATOCRIT; HEMODIALYSIS; HOLLOW FIBER; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; UREMIA;

ABSORPTIOMETRY, PHOTON; ADULT; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OSTEOPOROSIS; RENAL DIALYSIS; UREMIA;

EID: 37249051311     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02877703     Document Type: Article

References (22)

1. Hruska KA, Teitelbaum SL. Mechanisms of disease - renal osteodystrophy. N Engl J Med. 1995;333:166-174.
2. Ersoy FF. Osteoporosis in the elderly with chronic kidney disease. Int Urol Nephrol. 2007;39:321-331.
3. Lobao R, Carvalho AB, Cuppari L, et al. High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis. Clin Nephrol. 2004;62:432-439.
4. Lacativa PG, de Mendonca LM, de Mattos P, et al. Risk factors for decreased total body and regional bone mineral density in hemodialysis patients with severe secondary hyperparathyroidism. J Clin Densitom. 2005;8:352-361.
5. Malluche HH, Monier-Faugere MC. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol. 1994;4:1631-1642.
6. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:1-201.
7. Taal MW, Masud T, Green D, Cassidy MJ. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant. 1999;14:1922-1928.
8. Ersoy FF, Passadakis SP, Tam P, et al. Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients. J Bone Miner Metab. 2006;24:79-86.
9. Urena P, Bernard-Poenaru O, Ostertag A, et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant. 2003;18:2325-2331.
10. Kullenberg R, Falch JA. Prevalence of osteoporosis using bone mineral measurements at the calcaneus by dual X-ray and laser (DXL). Osteoporos Int. 2003;14:823-827.
11. Hampson G, Vaja S, Evans C, et al. Comparison of the humoral markers of bone turnover and bone mineral density in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephron. 2002;91:94-102.
12. Zayour D, Daouk M, Medawar W, Salamoun M, El-Hajj Fuleihan G. Predictors of bone mineral density in patients on hemodialysis. Transplant Proc. 2004;36:1297-1301.
13. Baszko-Blaszyk D, Grzegorzewska AE, Horst-Sikorska W, Sowinski J. Bone mass in chronic renal insufficiency patients treated with continuous ambulatory peritoneal dialysis. Adv Perit Dial. 2001;17:109-113.
14. Malyszko J, Brzosko S, Wolczynski S, Malyszko JS, Mysliwiec M. Bone metabolism in dialysis patients assessed by biochemical markers and densitometry. Pol Arch Med Wewn. 2003;110:967-972.
15. Yucel AE, Kart-Koseoglu H, Isiklar I, et al. Bone mineral density in patients on maintenance hemodialysis and effect of chronic hepatitis C virus infection. Ren Fail. 2004;26:159-164.
16. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36:1115-1121.
17. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006;70:1358-1366.
18. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131-2138.
19. Lemann J Jr, Bushinsky DA, Hamm LL. Bone buffering of acid and base in humans. Am J Physiol Renal Physiol. 2003;285:F811-F832.
20. Movilli E, Zani R, Carli O, et al. Direct effect of the correction of acidosis on plasma parathyroid hormone concentrations, calcium and phosphate in hemodialysis patients: a prospective study. Nephron. 2001;87:257-262.
21. Mathur RP, Dash SC, Gupta N, et al. Effects of correction of metabolic acidosis on blood urea and bone metabolism in patients with mild to moderate chronic kidney disease: a prospective randomized single blind controlled trial. Ren Fail. 2006;28:1-5.
22. Negri AL, Barone R, Quiroga MA, et al. Bone mineral density: serum markers of bone turnover and their relationships in peritoneal dialysis. Perit Dial Int. 2004;24:163-168.